ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday

ProKidney (NASDAQ:PROK) is expected to be announcing its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect ProKidney to post earnings of ($0.16) per share for the quarter.

ProKidney (NASDAQ:PROK) last released its earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $0.08 million for the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Stock Performance

PROK stock opened at $0.85 on Friday. ProKidney has a one year low of $0.46 and a one year high of $4.44. The company’s fifty day moving average price is $0.90 and its 200-day moving average price is $1.46. The company has a market capitalization of $249.96 million, a PE ratio of -1.55 and a beta of 1.52.

Insider Activity at ProKidney

In other ProKidney news, insider Control Empresarial De Capital purchased 268,105 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The shares were bought at an average price of $0.73 per share, with a total value of $195,716.65. Following the completion of the purchase, the insider now directly owns 72,862,330 shares in the company, valued at $53,189,500.90. This trade represents a 0.37 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have acquired a total of 1,787,716 shares of company stock valued at $1,175,419 over the last 90 days. 41.49% of the stock is owned by corporate insiders.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.